000281505 001__ 281505
000281505 005__ 20251102002045.0
000281505 0247_ $$2doi$$a10.1007/s00415-025-13401-9
000281505 0247_ $$2pmid$$apmid:40999034
000281505 0247_ $$2pmc$$apmc:PMC12464036
000281505 0247_ $$2ISSN$$a0367-004X
000281505 0247_ $$2ISSN$$a0012-1037
000281505 0247_ $$2ISSN$$a0340-5354
000281505 0247_ $$2ISSN$$a1432-1459
000281505 0247_ $$2altmetric$$aaltmetric:181726662
000281505 037__ $$aDZNE-2025-01126
000281505 041__ $$aEnglish
000281505 082__ $$a610
000281505 1001_ $$00000-0002-1296-577X$$aSchmidt, Claudia C$$b0
000281505 245__ $$aApraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer's pathology.
000281505 260__ $$a[Darmstadt]$$bSteinkopff$$c2025
000281505 3367_ $$2DRIVER$$aarticle
000281505 3367_ $$2DataCite$$aOutput Types/Journal article
000281505 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761739159_30626
000281505 3367_ $$2BibTeX$$aARTICLE
000281505 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281505 3367_ $$00$$2EndNote$$aJournal Article
000281505 520__ $$aApraxia represents a core feature of Alzheimer's disease (AD), a neurodegenerative disorder characterised by the accumulation of β-amyloid plaques and tau deposition. However, systematic descriptions of apraxic deficits in AD patients remain scarce. Here, we comprehensively investigate apraxia profiles and their link with cognitive impairment in patients with biomarker-verified Alzheimer's pathology. We characterised the frequency and patterns of apraxic deficits in patients with biomarker-verified Alzheimer's pathology using a battery of standardised apraxia tests. Demographic variables and apraxia scores were related to patients' general cognitive impairment using hierarchical regression analysis. Apraxic deficits were found in 67% of patients with biomarker-verified Alzheimer's pathology (n = 63). Patients with Alzheimer's pathology were more impaired in imitating finger gestures (than hand gestures: 89.2% vs. 80.0%, p < 0.001) and imitating complex hand movements (than single hand movements: 97.4% vs. 78.5%, p < 0.001), even when controlling for general cognitive impairment. Apraxia assessments explained about 60% of the variance in dementia severity, with performance in the KAS subtest of pantomiming object use (beta coefficient: 0.47, p = 0.001) and the DATE subtest for limb apraxia (beta coefficient: 0.37, p = 0.005) constituting significant predictors of general cognitive impairment. These findings emphasise the relevance of apraxia in patients with biomarker-verified Alzheimer's pathology, revealing that praxis deficits predict general cognitive impairment in AD. Further research is warranted into the role of apraxia as a potential early diagnostic criterion in AD.
000281505 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281505 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281505 650_7 $$2Other$$aAlzheimer’s disease
000281505 650_7 $$2Other$$aGesture imitation
000281505 650_7 $$2Other$$aLimb apraxia
000281505 650_7 $$2Other$$aMini-Mental State Examination (MMSE)
000281505 650_7 $$2Other$$aPantomime
000281505 650_7 $$2NLM Chemicals$$aBiomarkers
000281505 650_2 $$2MeSH$$aHumans
000281505 650_2 $$2MeSH$$aAlzheimer Disease: complications
000281505 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000281505 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000281505 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000281505 650_2 $$2MeSH$$aFemale
000281505 650_2 $$2MeSH$$aMale
000281505 650_2 $$2MeSH$$aAged
000281505 650_2 $$2MeSH$$aApraxias: etiology
000281505 650_2 $$2MeSH$$aApraxias: diagnosis
000281505 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000281505 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000281505 650_2 $$2MeSH$$aBiomarkers
000281505 650_2 $$2MeSH$$aAged, 80 and over
000281505 650_2 $$2MeSH$$aNeuropsychological Tests
000281505 650_2 $$2MeSH$$aMiddle Aged
000281505 650_2 $$2MeSH$$aGestures
000281505 7001_ $$aBardakan, Michella M$$b1
000281505 7001_ $$aJaeger, Elena$$b2
000281505 7001_ $$aRichter, Nils$$b3
000281505 7001_ $$aBischof, Gérard N$$b4
000281505 7001_ $$aGiehl, Kathrin$$b5
000281505 7001_ $$aOnur, Oezguer A$$b6
000281505 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b7$$udzne
000281505 7001_ $$aFink, Gereon R$$b8
000281505 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b9$$udzne
000281505 7001_ $$aWeiss, Peter H$$b10
000281505 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-025-13401-9$$gVol. 272, no. 10, p. 654$$n10$$p654$$tJournal of neurology$$v272$$x0367-004X$$y2025
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126%20SUP.docx
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126.pdf$$yOpenAccess
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126%20SUP.doc
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126%20SUP.odt
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126%20SUP.pdf
000281505 8564_ $$uhttps://pub.dzne.de/record/281505/files/DZNE-2025-01126.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281505 909CO $$ooai:pub.dzne.de:281505$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281505 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000032$$aExternal Institute$$b7$$kExtern
000281505 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000281505 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281505 9141_ $$y2025
000281505 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281505 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000281505 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
000281505 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000281505 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281505 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
000281505 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000281505 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000281505 980__ $$ajournal
000281505 980__ $$aVDB
000281505 980__ $$aUNRESTRICTED
000281505 980__ $$aI:(DE-2719)1011202
000281505 9801_ $$aFullTexts